Troxell B, Mendoza M, Ali R, Koci M, Hassan H
Vaccines (Basel). 2020; 8(4).
PMID: 33153043
PMC: 7711481.
DOI: 10.3390/vaccines8040646.
Lee J, Chaudhari A, Oh I, Eo S, Park S, Jawale C
Can J Vet Res. 2015; 79(3):229-34.
PMID: 26130856
PMC: 4445516.
Galen J, Wang J, Carrasco J, Lloyd S, Mellado-Sanchez G, Diaz-McNair J
Infect Immun. 2014; 83(1):161-72.
PMID: 25332120
PMC: 4288866.
DOI: 10.1128/IAI.02443-14.
Zhang J, De Masi L, John B, Chen W, Schifferli D
Microb Cell Fact. 2014; 13:80.
PMID: 24898796
PMC: 4055283.
DOI: 10.1186/1475-2859-13-80.
Zheng S, Yu B, Zhang K, Chen M, Hua Y, Yuan S
BMC Immunol. 2012; 13:54.
PMID: 23013063
PMC: 3503649.
DOI: 10.1186/1471-2172-13-54.
Extracellular matrix formation enhances the ability of Streptococcus pneumoniae to cause invasive disease.
Trappetti C, Ogunniyi A, Oggioni M, Paton J
PLoS One. 2011; 6(5):e19844.
PMID: 21611130
PMC: 3097209.
DOI: 10.1371/journal.pone.0019844.
Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.
Wang S, Li Y, Shi H, Sun W, Roland K, Curtiss 3rd R
Infect Immun. 2010; 79(2):937-49.
PMID: 21134969
PMC: 3028866.
DOI: 10.1128/IAI.00445-10.
Development of non-antibiotic-resistant, chromosomally based, constitutive and inducible expression systems for aroA-attenuated Salmonella enterica Serovar Typhimurium.
Matic J, Terry T, van Bockel D, Maddocks T, Tinworth D, Jennings M
Infect Immun. 2009; 77(5):1817-26.
PMID: 19223478
PMC: 2681777.
DOI: 10.1128/IAI.01301-08.
Tolerance in the absence of autoantigen.
Pascual D, Ochoa-Reparaz J, Rynda A, Yang X
Endocr Metab Immune Disord Drug Targets. 2007; 7(3):203-10.
PMID: 17897047
PMC: 9811400.
DOI: 10.2174/187153007781662549.
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
Yang X, Hinnebusch B, Trunkle T, Bosio C, Suo Z, Tighe M
J Immunol. 2007; 178(2):1059-67.
PMID: 17202369
PMC: 9809976.
DOI: 10.4049/jimmunol.178.2.1059.
Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium.
Garmory H, Leckenby M, Griffin K, Elvin S, Taylor R, Hartley M
Infect Immun. 2005; 73(4):2005-11.
PMID: 15784541
PMC: 1087430.
DOI: 10.1128/IAI.73.4.2005-2011.2005.
Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines.
Vindurampulle C, Attridge S
Infect Immun. 2002; 71(1):287-97.
PMID: 12496178
PMC: 143414.
DOI: 10.1128/IAI.71.1.287-297.2003.
Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines.
McNeill H, Sinha K, Hormaeche C, Lee J, Khan C
Appl Environ Microbiol. 2000; 66(3):1216-9.
PMID: 10698796
PMC: 91967.
DOI: 10.1128/AEM.66.3.1216-1219.2000.
Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium.
Dunstan S, Simmons C, Strugnell R
Infect Immun. 1999; 67(10):5133-41.
PMID: 10496887
PMC: 96862.
DOI: 10.1128/IAI.67.10.5133-5141.1999.
Polymeric display of immunogenic epitopes from herpes simplex virus and transmissible gastroenteritis virus surface proteins on an enteroadherent fimbria.
Rani D, Bayer M, Schifferli D
Clin Diagn Lab Immunol. 1999; 6(1):30-40.
PMID: 9874660
PMC: 95656.
DOI: 10.1128/CDLI.6.1.30-40.1999.
Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity.
Ascon M, Hone D, Walters N, Pascual D
Infect Immun. 1998; 66(11):5470-6.
PMID: 9784559
PMC: 108685.
DOI: 10.1128/IAI.66.11.5470-5476.1998.
Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters.
McSorley S, Xu D, Liew F
Infect Immun. 1997; 65(1):171-8.
PMID: 8975908
PMC: 174572.
DOI: 10.1128/iai.65.1.171-178.1997.
Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing.
Denich K, Borlin P, OHanley P, Howard M, Heath A
Infect Immun. 1993; 61(11):4818-27.
PMID: 8406883
PMC: 281239.
DOI: 10.1128/iai.61.11.4818-4827.1993.
Development of mucosal protection against the heat-stable enterotoxin (ST) of Escherichia coli by oral immunization with a genetic fusion delivered by a bacterial vector.
Cardenas L, Clements J
Infect Immun. 1993; 61(11):4629-36.
PMID: 8406860
PMC: 281214.
DOI: 10.1128/iai.61.11.4629-4636.1993.
Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR.
Wu S, Pascual D, Vancott J, McGhee J, Maneval Jr D, Levine M
Infect Immun. 1995; 63(12):4933-8.
PMID: 7591160
PMC: 173709.
DOI: 10.1128/iai.63.12.4933-4938.1995.